| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $288,872 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Evans Daron | CFO | 3 | $161,244 | 0 | $0 | $161,244 |
| Elam Nevan C | CEO | 1 | $50,880 | 0 | $0 | $50,880 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 1 | $47,600 | 0 | $0 | $47,600 |
| Karnawat Sunil Ratilal | Chief Commercial Officer | 1 | $19,599 | 0 | $0 | $19,599 |
| Hogenhuis Wladimir | director | 1 | $9,549 | 0 | $0 | $9,549 |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed …
Over the last 12 months, insiders at Rezolute, Inc. have bought $288,872 and sold $0 worth of Rezolute, Inc. stock.
On average, over the past 5 years, insiders at Rezolute, Inc. have bought $4.57M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Evans Daron (CFO) — $161,244. Elam Nevan C (CEO) — $50,880. ROBERTS BRIAN KENNETH (Chief Medical Officer) — $47,600.
The last purchase of 10,000 shares for transaction amount of $28,500 was made by Evans Daron (CFO) on 2026‑03‑30.
| 2026-03-30 | Evans Daron | CFO | 10,000 0.0104% | $2.85 | $28,500 | +45.61% | ||
| 2025-12-16 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 28,000 0.0254% | $1.70 | $47,600 | +79.70% | ||
| 2025-12-16 | Hogenhuis Wladimir | director | 5,650 0.0051% | $1.69 | $9,549 | +79.70% | ||
| 2025-12-15 | Elam Nevan C | CEO | 32,000 0.0338% | $1.59 | $50,880 | +122.70% | ||
| 2025-12-15 | Evans Daron | CFO | 45,000 0.0528% | $1.77 | $79,578 | +122.70% | ||
| 2025-12-15 | Karnawat Sunil Ratilal | Chief Commercial Officer | 12,100 0.013% | $1.62 | $19,599 | +122.70% | ||
| 2025-12-09 | Evans Daron | CFO | 10,549 0.0185% | $5.04 | $53,167 | -63.20% | ||
| 2025-06-25 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 2,500 0.0029% | $4.38 | $10,939 | 0.00% | ||
| 2025-06-24 | Evans Daron | CFO | 5,000 0.0058% | $4.05 | $20,250 | +2.12% | ||
| 2025-06-13 | Kim Young-Jin | director | 1.23M 1.1136% | $3.25 | $4M | -2.50% | ||
| 2025-06-13 | KREHER NERISSA | director | 3,076 0.0028% | $3.25 | $9,997 | -2.50% | ||
| 2025-03-31 | Hogenhuis Wladimir | director | 6,758 0.0112% | $2.92 | $19,733 | +48.62% | ||
| 2025-03-27 | Elam Nevan C | CEO | 12,302 0.0198% | $2.85 | $34,999 | +47.60% | ||
| 2025-03-26 | Evans Daron | CFO | 20,000 0.0349% | $2.88 | $57,700 | +57.88% | ||
| 2025-02-18 | Hogenhuis Wladimir | director | 10,000 0.0168% | $4.70 | $47,000 | -8.80% | ||
| 2024-12-18 | Evans Daron | CFO | 10,000 0.0181% | $4.29 | $42,900 | +21.69% | ||
| 2024-12-12 | Evans Daron | CFO | 9,000 0.0155% | $4.60 | $41,400 | +7.00% | ||
| 2024-09-24 | Hogenhuis Wladimir | director | 4,259 0.0075% | $4.70 | $20,017 | +2.99% | ||
| 2024-06-25 | Kim Young-Jin | director | 1.25M 2.5143% | $4.00 | $5M | +16.93% | ||
| 2024-06-25 | Hogenhuis Wladimir | director | 4,815 0.01% | $4.15 | $19,982 | +16.93% |
| Elam Nevan C | CEO | 641119 0.6628% | $2.57M | 3 | 0 | +114.05% |
| Evans Daron | CFO | 414462 0.4285% | $1.66M | 14 | 0 | +67.02% |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 308352 0.3188% | $1.24M | 13 | 0 | +78.91% |
| Hogenhuis Wladimir | director | 119675 0.1237% | $479,896.75 | 7 | 0 | <0.0001% |
| Karnawat Sunil Ratilal | Chief Commercial Officer | 71542 0.074% | $286,883.42 | 1 | 0 | |
| Genexine Inc. | 10 percent owner | 91300933 94.3949% | $366.12M | 1 | 0 | |
| Kim Young-Jin | director | 8423386 8.7088% | $33.78M | 4 | 0 | +34.18% |
| HANDOK, INC. | 5942617 6.144% | $23.83M | 72 | 0 | <0.0001% | |
| Welch David F | director | 1811415 1.8728% | $7.26M | 13 | 0 | |
| CHU JUE MIN | 10 percent owner | 893750 0.924% | $3.58M | 1 | 0 | |
| Labrucherie Gil M | director | 53572 0.0554% | $214,823.72 | 1 | 0 | <0.0001% |
| KREHER NERISSA | director | 37576 0.0388% | $150,679.76 | 1 | 0 | <0.0001% |
| WOLKIN ORIT | 10 percent owner | 0 0% | $0 | 1 | 1 | |
| KAEYO INVESTMENTS LTD | 10 percent owner | 0 0% | $0 | 1 | 1 | |
| BAR NIR | President and Treasurer | 0 0% | $0 | 1 | 1 |
$3,887,391 | 114 | 13.01% | $433.37M | |
Rezolute, Inc. (RZLT) | $31,123,523 | 108 | 6.46% | $387.86M |
$24,384,691 | 42 | -30.27% | $396.82M | |
$2,481,409 | 33 | 201.68% | $455.48M | |
$22,020,194 | 25 | 38.25% | $405.58M |
| Increased Positions | 86 | +66.67% | 42M | +48.15% |
| Decreased Positions | 59 | -45.74% | 38M | -43.86% |
| New Positions | 40 | New | 14M | New |
| Sold Out Positions | 35 | Sold Out | 24M | Sold Out |
| Total Postitions | 156 | +20.93% | 91M | +4.29% |
| Federated Hermes, Inc. | $30,385.00 | 15.09% | 14.03M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $27,635.00 | 13.73% | 12.76M | -47,643 | -0.37% | 2025-09-30 |
| Blackrock, Inc. | $10,835.00 | 5.38% | 5M | +922,911 | +22.61% | 2025-09-30 |
| Siren, L.L.C. | $10,544.00 | 5.24% | 4.87M | +5M | New | 2025-09-30 |
| Vanguard Group Inc | $9,548.00 | 4.74% | 4.41M | +387,502 | +9.63% | 2025-09-30 |
| Blackstone Inc. | $6,547.00 | 3.25% | 3.02M | -536,390 | -15.07% | 2025-09-30 |
| Mangrove Partners Im, Llc | $6,240.00 | 3.1% | 2.88M | +584,660 | +25.45% | 2025-09-30 |
| Marshall Wace, Llp | $5,907.00 | 2.93% | 2.73M | -158,166 | -5.48% | 2025-09-30 |
| Ubs Group Ag | $5,837.00 | 2.9% | 2.7M | -341,190 | -11.23% | 2025-09-30 |
| Great Point Partners I Lp | $5,308.00 | 2.64% | 2.45M | -581,653 | -19.18% | 2025-09-30 |